Ixekizumab for Non-Radiographic Axial Spondyloarthritis Tops SPT Week in Review

5. Nivolumab-Ipilimumab Combo Receives FDA Breakthrough Designation for Advanced Hepatocellular Carcinoma

FDA breakthrough designation is based on data for nivolumab plus ipilimumab in a study evaluating the immuno-oncology combination in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Read more.

4. Teva to Resume Production of Vincristine After Widespread Shortages

With vincristine in short supply, Teva will resume production of the chemotherapy agent following its previous decision to remove the product from the market. Read more.

3. Intravenous Immunoglobulin Deemed Safe in Pediatric Patients

IVIG found to have a good safety profile in pediatric patients, with low risk of severe adverse drug reactions. Read more.

2. Zanubrutinib Granted Accelerated Approval for Second-Line Treatment of Mantle Cell Lymphoma

The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for the treatment of mantle cell lymphoma in adults who have received at least 1 prior therapy. Read more.

1. Study: Ixekizumab Improves Symptoms of Non-Radiographic Axial Spondyloarthritis

The COAST-X study evaluated ixekizumab (Taltz, Eli Lilly) in patients with non-radiographic axial spondyloarthritis. Read more.